JP2023529845A - 眼の障害の治療のための化合物及び方法 - Google Patents

眼の障害の治療のための化合物及び方法 Download PDF

Info

Publication number
JP2023529845A
JP2023529845A JP2022574480A JP2022574480A JP2023529845A JP 2023529845 A JP2023529845 A JP 2023529845A JP 2022574480 A JP2022574480 A JP 2022574480A JP 2022574480 A JP2022574480 A JP 2022574480A JP 2023529845 A JP2023529845 A JP 2023529845A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022574480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529845A5 (https=
Inventor
ケリー，ダレン
パパディミトリウ，ミシェル
バーンズ，クリス
ダニエルズ，エリック
Original Assignee
オキュルクス プロプライエタリー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901858A external-priority patent/AU2020901858A0/en
Application filed by オキュルクス プロプライエタリー リミテッド filed Critical オキュルクス プロプライエタリー リミテッド
Publication of JP2023529845A publication Critical patent/JP2023529845A/ja
Publication of JP2023529845A5 publication Critical patent/JP2023529845A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022574480A 2020-06-05 2021-06-03 眼の障害の治療のための化合物及び方法 Pending JP2023529845A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2020901858A AU2020901858A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
AU2020901856 2020-06-05
AU2020901858 2020-06-05
AU2020901856A AU2020901856A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
PCT/US2021/035749 WO2021247900A1 (en) 2020-06-05 2021-06-03 Compounds and methods for the treatment of eye disorders

Publications (2)

Publication Number Publication Date
JP2023529845A true JP2023529845A (ja) 2023-07-12
JP2023529845A5 JP2023529845A5 (https=) 2024-05-15

Family

ID=78829970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574480A Pending JP2023529845A (ja) 2020-06-05 2021-06-03 眼の障害の治療のための化合物及び方法

Country Status (11)

Country Link
US (1) US20230270703A1 (https=)
EP (1) EP4161527A4 (https=)
JP (1) JP2023529845A (https=)
KR (1) KR20230024331A (https=)
CN (1) CN116033901A (https=)
AU (1) AU2021284380A1 (https=)
BR (1) BR112022024728A2 (https=)
CA (1) CA3185849A1 (https=)
IL (1) IL298733A (https=)
MX (1) MX2022015327A (https=)
WO (2) WO2021247900A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511990A (ja) * 2021-03-17 2024-03-18 オキュルクス プロプライエタリー リミテッド 障害の処置用の化合物ならびにその塩および多形体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339814A (ja) * 1986-08-01 1988-02-20 Teisan Seiyaku Kk トラニラストの経口用持続性製剤
WO1997029744A1 (en) * 1996-02-15 1997-08-21 Kissei Pharmaceutical Co., Ltd. Neovascularization inhibitor
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
WO1998047504A1 (en) * 1997-04-18 1998-10-29 Kissei Pharmaceutical Co., Ltd. Preventives or remedies for diseases affecting excessive proliferation of retinal pigment epithelial cells
JP2014502267A (ja) * 2010-11-24 2014-01-30 フィブロテック セラピューティクス プロプライエタリー リミテッド 炎症及び血管増殖に関連する眼疾患の治療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526041T1 (de) * 2001-12-11 2011-10-15 Fibrogen Inc Verfahren zur hemmung okularer vorgänge
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2830024T3 (es) * 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
JP2011006406A (ja) * 2009-05-29 2011-01-13 Santen Pharmaceut Co Ltd トラニラストを含有する網膜疾患の予防または治療剤
US10780070B2 (en) * 2013-10-18 2020-09-22 The Schepens Eye Research Institute, Inc. Alpha-aminoadipate for treatment of vision loss and restoring sight

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339814A (ja) * 1986-08-01 1988-02-20 Teisan Seiyaku Kk トラニラストの経口用持続性製剤
WO1997029744A1 (en) * 1996-02-15 1997-08-21 Kissei Pharmaceutical Co., Ltd. Neovascularization inhibitor
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
WO1998047504A1 (en) * 1997-04-18 1998-10-29 Kissei Pharmaceutical Co., Ltd. Preventives or remedies for diseases affecting excessive proliferation of retinal pigment epithelial cells
JP2014502267A (ja) * 2010-11-24 2014-01-30 フィブロテック セラピューティクス プロプライエタリー リミテッド 炎症及び血管増殖に関連する眼疾患の治療法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"A Phase I, randomised, double blind, placebo-controlled, dose-escalating study of the safety, tolera", AUSTRALIAN NEW ZEALAND CLINICAL TRIALS REGISTRY (ANZCTR), [ONLINE], JPN6025019998, 2019, pages 12619001607167, ISSN: 0005597260 *
"Oral administration of the novel small molecule drug OCX063 protects against inflammation and vascul", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 60, JPN6025019999, 2019, pages 5356, ISSN: 0005597259 *
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, JPN6025020000, 2013, pages 6868 - 6873, ISSN: 0005717507 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511990A (ja) * 2021-03-17 2024-03-18 オキュルクス プロプライエタリー リミテッド 障害の処置用の化合物ならびにその塩および多形体

Also Published As

Publication number Publication date
AU2021284380A1 (en) 2023-01-19
EP4161527A4 (en) 2024-06-26
US20230270703A1 (en) 2023-08-31
KR20230024331A (ko) 2023-02-20
IL298733A (en) 2023-02-01
MX2022015327A (es) 2023-02-22
WO2021247900A1 (en) 2021-12-09
CA3185849A1 (en) 2021-12-09
BR112022024728A2 (pt) 2023-03-07
WO2021247901A1 (en) 2021-12-09
CN116033901A (zh) 2023-04-28
EP4161527A1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
US10251867B2 (en) Dosing regimen for a selective S1P1 receptor agonist
US7820712B2 (en) Uses of ion channel modulating compounds
US20210353579A1 (en) High penetration compositions and uses thereof
EP3749303A1 (en) Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
JPH03181422A (ja) 炎症の治療方法及び炎症の治療用合成薬
CA2524034A1 (en) Uses of ion channel modulating compounds
CN113453677A (zh) 用于治疗急性心房颤动的舒卡定施用
JP2022516796A (ja) 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用
WO2006123676A1 (ja) 角結膜障害の予防または治療剤
JP2023529845A (ja) 眼の障害の治療のための化合物及び方法
JP2018502915A (ja) 炎症及び疼痛の治療のための組成物及び方法
CN120713906A (zh) 用于治疗代谢失调的组合物和方法
CN107613970A (zh) 短效苯基烷基胺钙通道阻滞剂的高水溶性盐及其应用
CN101015556B (zh) 窦房结If电流抑制剂与钙抑制剂的组合以及含有它的药物组合物
CN105992758B (zh) 包括含硫部分的糖衍生物和制备它们的方法以及使用它们治疗mps iiic的方法
AU778148B2 (en) 2-aminotetralin derivatives for the therapy of glaucoma
JP2023529845A5 (https=)
US20110224200A1 (en) Therapeutic agent for chorioretinal degenerative disease containing pyridine-3-carbaldehyde 0-(piperidin-1-yl-propyl)-oxime derivative as active ingredient
KR20210046115A (ko) 니아신 유도체 및 이를 함유하는 약학 조성물
EP2119440A1 (en) Amidino derivatives for use in the prevention or treatment of retinitis pigmentosa and Leber's disease
HK40061591A (en) Sulcardine administration for treatment of acute atrial fibrillation
JP2018504439A (ja) 粘膜炎の治療のための組成物及び方法
JP2024511990A (ja) 障害の処置用の化合物ならびにその塩および多形体
JP2002241304A (ja) 前眼部炎症疾患の予防または治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240501

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251028